The Intersection of HIV, Diabetes, and Race: Exploring Disparities in Diabetes Care among People Living with HIV

Karla I. Galaviz, PhD1, Rincy Varughese, MPH1, Brian K. Agan, MD3,4, Vincent C. Marconi, MD1,2,5,6, Xiuping Chu, PhD3,4, Seung Hyun Won, PhD3,4, Anuradha Ganesan, MD3,4,7, Mohammed K. Ali, MD1,8, and Jonathan Colasanti, MD, MSPH1,5,6

Abstract
In a setting of universal health care access, we compared diabetes control between Caucasians and African Americans (AA) living with HIV. This was a cross-sectional analysis of data from a cohort study among military members living with HIV and diabetes. Using adjusted logistic regression models, we compared proportions of Caucasians and AA meeting the following diabetes treatment goals: hemoglobin A1c <7.0%, blood pressure (BP) <140/90 mm Hg, low density lipoprotein cholesterol <100 mg/dL, and not smoking. We included 107 Caucasian (mean age 37 years) and 126 AA (mean age 33 years) participants. A similar proportion of Caucasians and AA were prescribed diabetes (60%) and BP (80%) medications. Yet, more Caucasians met the BP treatment goal (77% [54%, 90%]) than AA (61% [36%, 82%]). Thus, more Caucasians met the combined A1c, BP, and cholesterol goals for diabetes control (25% [10%, 49%]) than AA (13% [5%, 31%]). Despite having equal access to health care, AA in this study have poorer diabetes control than Caucasians.

Keywords
care continuum, patient care, race, equity

Date received: 09 May 2019; revised: 08 December 2019; accepted: 08 January 2020.

Introduction
The HIV and type 2 diabetes epidemics are converging in the US. The national diabetes prevalence in people living with HIV (PWH) is 10%, which is 4% higher than in the general population.1-3 African Americans are disproportionally affected as those living with HIV experience higher rates of diabetes, obesity, and hypertension than their Caucasian counterparts.4,5 Though there is evidence that African Americans are less likely to achieve blood pressure (BP) control than Caucasians, racial disparities have not been explored in the context of diabetes management in the HIV population, where African American communities are already disproportionately impacted.

Disentangling whether health disparities are due to race or socioeconomic status (SES) is challenging. Race and SES are highly correlated and both affect health outcomes, either independently or in conjunction.7 For instance, low SES individuals

1 Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA
2 Infectious Disease Section, Atlanta VA Medical Center, Atlanta, GA, USA
3 Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
4 Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
5 Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
6 Infectious Disease Program, Grady Health System, Atlanta, GA, USA
7 Division of Infectious Diseases, Walter Reed National Military Medical Center, Bethesda, MD, USA
8 Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA, USA

Corresponding Author:
Karla I. Galaviz, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, CNR Building Room 6011, Atlanta, GA, USA.
Email: kgalaviz@emory.edu.
What Do We Already Know about This Topic?

African Americans living with HIV experience higher rates of diabetes than their Caucasian counterparts; whether diabetes control differs by race has not been explored.

How Does Your Research Contribute to the Field?

Our study shows that despite having equal access to health care and equivalent HIV control, African Americans have lower rates of blood pressure control and thus overall diabetes control than Caucasians.

What Are Your Research’s Implications toward Theory, Practice, or Policy?

In order to maintain the gains in life expectancy achieved through successful HIV management, factors associated with blood pressure control disparities should be identified and addressed.

in the US are less likely to visit a doctor than high SES individuals,\textsuperscript{8} while low SES is associated with an inconsistent patient–provider relationship.\textsuperscript{9} Furthermore, African Americans have been found to have poorer access to care and health insurance coverage than Caucasians.\textsuperscript{10} Exploring diabetes control among PWH with equal access to health care could help disentangle the impact of race on chronic disease control disparities.

Thus, the aim of this study was to compare diabetes control between African American and Caucasian military members living with HIV who have open-access to Department of Defense healthcare and medications. For this, we mirrored the HIV control approach from the HIV care continuum,\textsuperscript{11} which has offered lessons for diabetes control in the general\textsuperscript{12} and HIV populations.\textsuperscript{13} This study aligns with calls made for diabetes clinical guidelines to include recommendations for addressing social determinants in patient-centered treatment plans.\textsuperscript{14}

Methods

Study Design and Population

We conducted a cross-sectional analysis using data from the US Military HIV Natural History Study (NHS) from 2011 to 2015. The NHS is an ongoing prospective cohort study conducted at 6 military treatment facilities focused on exploring the natural history of HIV among military beneficiaries.\textsuperscript{15} Since 1986, the NHS has enrolled 6008 active duty members/Department of Defense beneficiaries with HIV and has over 1500 active participants at present.\textsuperscript{16} The NHS participants are seen every 6 months by an HIV study specialist where data on demographic characteristics, markers of HIV disease progression, medication use, and clinical events are collected through interview and electronic medical record abstraction.

From the NHS participant pool, we identified Caucasian and African American participants with diabetes defined as follows: (1) clinician diagnosis confirmed by a subsequent antidiabetes medication prescription; or (2) 2 fasting blood glucose measures $\geq 7.0$ mmol/L ($\geq 126$ mg/dL) separated by at least 24 hours; or (3) fasting blood glucose $\geq 7.0$ mmol/L concurrent with a hemoglobin A\textsubscript{1c} ($A_{1c}$) measure $\geq 47.5$ mmol/mol ($\geq 6.5\%$); or (4) a single $A_{1c}$ measure $\geq 47.5$ mmol/mol confirmed by antidiabetes medication prescription or by a fasting blood glucose measure $\geq 7.0$ mmol/L. Among NHS participants with diabetes, we included those with data on viral suppression, $A_{1c}$, systolic and diastolic blood pressure, low density lipoprotein (LDL) cholesterol, and self-report of smoking at any single visit between 2011 and 2015 after diabetes diagnosis.

Variable Definitions

Self-reported Caucasian or African American race was the main exposure. Demographic covariates included sex, age at HIV diagnosis (proxy for participant age), participant rank (proxy for SES), and US region. Clinical covariates included time since diabetes diagnosis, body mass index (BMI, calculated as weight [kg]/height\textsuperscript{2} [meters]), Nadir and last CD4 cell count, and HIV viral load. Proportion of participants on medication was determined using prescription data for diabetes, hypertension, hyperlipidemia, and HIV obtained from NHS and centralized pharmacy records.

Diabetes treatment goals were based on the American Diabetes Association 2019 standards.\textsuperscript{17} Glycemic control was defined as achieving an $A_{1c}$ $<53$ mmol/mol (7.0%). Blood pressure (BP) control was defined as systolic BP $<140$ mm Hg and diastolic BP $<90$ mm Hg. Cholesterol control was defined as LDL $<2.59$ mmol/L (100 mg/dL), $A_{1c}$, BP, and cholesterol (ABC) control was defined as achieving all 3 targets, while ABC control plus nonsmoking also required participants not to smoke. Viral suppression was defined as the last HIV-1 RNA being $<200$ copies/$\mu$L.

Data Analyses

Data from the last available visit between 2011 and 2015 after diabetes diagnosis was used for analyses. Demographic and clinical characteristics were compared by race using $\chi^2$ or Fisher exact tests for categorical variables and $t$ tests for continuous variables. Crude percentages of participants achieving diabetes treatment goals and viral suppression were obtained by race. Based on these, we created low-, medium- and high-risk categories for each treatment goal and estimated the proportion of participants falling in each risk category. Fisher exact tests were used to compare these proportions by race. Logistic regression models were fitted to estimate the predicted
prevalence of achieving the A1c, BP, LDL cholesterol, and ABC goals by race. Factors associated with poor control for each treatment goal were also explored through logistic regression models. Models were adjusted for age at HIV diagnosis, sex, study region, study year, rank, years since diabetes diagnosis, and medication use (for diabetes, BP, cholesterol, or all 3). Reported \( P \) values are 2-sided with those <.05 deemed statistically significant. Analyses were conducted using SAS version 9.4 (SAS Institute Inc 2013; Cary, North Carolina).

Ethical Approval and Informed Consent

The NHS has been approved centrally by the Uniformed Services University Institutional Review Board and at each participating site and is conducted according to the principles expressed in the Declaration of Helsinki. All participants provided written informed consent. The Emory University Institutional Review Board determined the present retrospective data analysis did not require board review.

Results

From the 640 NHS participants with diabetes, 233 (36.4%) had complete data and were included in analyses (Caucasian N = 107 [97% male], African American N = 126 [94% male]). Included participants were older (35 versus 33 years, \( P = .009 \)), had higher BMI (28.6 versus 27.6 kg/m\(^2\), \( P = .02 \)), had higher diabetes duration (11 versus 7 years, \( P < .001 \)), and more were on active duty (91% versus 83%, \( P = .004 \)) than excluded participants (Supplemental Digital Content 1). Among included participants, Caucasians were 4 years older when they were diagnosed with HIV (36.7 versus 33.0 years, \( P = .03 \)) and had lower BMI (27.4 versus 29.6 kg/m\(^2\), \( P = .002 \)) than African Americans (Table 1). A similar proportion of Caucasian and African American participants were prescribed BP medication (80% versus 80%), yet, African Americans had higher systolic (134.0 versus 126.5 mm Hg, \( P = .006 \)) and diastolic BP (83.0 versus 77.2 mm Hg, \( P < .001 \)) than Caucasians. More Caucasians than African Americans were prescribed cholesterol medication (90% versus 68%, \( P < .0001 \)), while LDL cholesterol was higher in African Americans (103.3 versus 92.1 mg/dL, \( P = .009 \)).

Crude proportions of Caucasian/African American participants achieving HIV and diabetes treatment goals are the following: 95%/94% for viral suppression, 79%/79% for A1c, 77%/60% for BP, 65%/48% for LDL cholesterol, 82%/85% for not smoking, 40%/22% for combined ABC goals, and 31%/18% for combined ABC goals plus not smoking (Supplemental Digital Content 2). Table 2 shows mean values for each

Table 1. Demographic and Clinical Participant Characteristics by Race.

| Characteristics                     | Caucasian (n = 107) | African American (n = 126) | P     |
|-------------------------------------|--------------------|---------------------------|-------|
| Age at HIV diagnosis (years)        | 36.7 (9.9)         | 33.0 (9.0)                | .026  |
| BMI (kg/m\(^2\))                    | 27.4 (5.1)         | 29.6 (5.1)                | .002  |
| Nadir CD4 count (cells/mm\(^3\))   | 227.7 (145.4)      | 255.6 (170.0)             | .184  |
| Last CD4 count (cells/mm\(^3\))    | 687.4 (307.0)      | 747.3 (368.9)             | .177  |
| Diabetes duration (years)           | 8.7 (5.0)          | 8.7 (5.7)                 | .938  |
| Sex                                 |                    |                           |       |
| Male                                | 104 (97.2)         | 118 (93.7)                | .240  |
| Female                              | 3 (2.8)            | 8 (6.4)                   |       |
| Rank                                |                    |                           | .073  |
| Active duty                         | 94 (87.9)          | 119 (94.4)                |       |
| No active duty\(^a\)                | 13 (12.2)          | 7 (5.6)                   |       |
| Region                              |                    |                           | .005  |
| South\(^b\)                         | 75 (70.1)          | 108 (85.7)                |       |
| West                                | 22 (20.6)          | 8 (6.4)                   |       |
| Midwest                             | 6 (5.6)            | 3 (2.4)                   |       |
| Northeast\(^c\)                     | 4 (3.74)           | 7 (5.6)                   |       |
| Medication use                      |                    |                           |       |
| Diabetes                            | 67 (62.6)          | 74 (58.7)                 | .545  |
| Blood pressure                      | 86 (80.2)          | 101 (80.2)                | .967  |
| Cholesterol                         | 96 (89.7)          | 86 (68.3)                 | <.0001|
| ART                                 | 105 (98.1)         | 120 (95.2)                | .227  |
| Hemoglobin A1c (%)                  | 6.2 (1.2)          | 6.6 (1.5)                 | .058  |
| Systolic blood pressure (mm Hg)     | 126.5 (14.1)       | 134.0 (16.0)              | .006  |
| Diastolic blood pressure (mm Hg)    | 77.2 (9.4)         | 83.0 (10.1)               | <.0001|
| LDL cholesterol (mg/dL)             | 92.1 (35.2)        | 103.3 (28.2)              | .009  |

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; LDL, low density lipoprotein; SD, standard deviation.

\(^a\)Includes N/A or missing.

\(^b\)Includes Puerto Rico.

\(^c\)Includes Armed Forces.
diabetes treatment goal and the proportion of participants fall- ing in the low-, medium-, and high-risk categories for each treatment goal. This shows more African Americans than Caucasians fell in the high-risk category for systolic BP (≥140 mm Hg, 32.7% versus 17.8%, P = .011) and diastolic BP (≥90 mm Hg, 26.2% versus 11.0%, P = .011) among those not using therapy. Proportions achieving A1c and cholesterol treatment goals were similar in both groups (Table 3). Those living with diabetes for ≥5 years were less likely to have uncontrolled BP (Caucasians odds ratio [OR] = 0.30 [0.11-0.84], African American OR = 0.41 [0.17 0.95]). Those not using diabetes medication were less likely to have uncontrolled A1c (Caucasian OR = 0.03 [0.002-0.41], African Americans OR = 0.07 [0.01-0.36]).

**Discussion**

Comparing diabetes control between Caucasians and African Americans living with HIV and with open health care access, we found HIV and A1c control were optimal, with over 90% of African Americans and Caucasians achieving viral suppression and glycemic control. However, only 25% of Caucasians and 13% of African Americans achieved optimal diabetes control. Despite having equal access to health care and equivalent HIV control, African Americans had lower rates of BP control and thus poorer ABC control than Caucasians. Over 70% of our study sample was from the US south, suggesting this region is not only facing an unprecedented HIV epidemic but also a high prevalence of cardiometabolic comorbidities in the HIV population. Strategies to improve diabetes control in this population are imperative, especially those that respond to individual needs and social determinants of health.

In line with previous reports,13 we found HIV control is achieved more often than that of cardiometabolic diseases like diabetes. Suboptimal diabetes management has also been observed among women living with HIV, with adjusted estimates showing only 12% achieve ABC control.13 The higher ABC control rates observed in our study suggests access to free/low cost health care and medications contribute to better diabetes outcomes. However, our findings also show healthcare access is not sufficient to achieve optimal diabetes control; only 13% African American and 25% Caucasian participants in this analysis achieved ABC control compared to 27% in the general US population.12 Cardiovascular and chronic kidney disease disproportionately affect PWH4,5 and unless risk factors like diabetes are effectively addressed, the disproportionate burden will only increase.

Despite having comparable hypertension treatment levels, African Americans in this study had lower rates of BP control and thus ABC control than Caucasians, which mirrors previous observations in PWH.6 Among active-duty Air Force members, African Americans have been found to have a higher prevalence of hypertension and dyslipidemia than Caucasians.18 Whether these differences are due to biological factors or

### Table 2. Proportion of Participants Falling in the Low-, Medium-, and High-Risk Categories and Corresponding Mean Values for Different Treatment Goals by Race.

| Risk Category | Caucasian (n = 107) | African American (n = 126) |
|---------------|-------------------|--------------------------|
|               | Mean (SD)         | n (%) on Category | n (%) on Medication | Mean (SD)       | n (%) on Category | n (%) on Medication | P* |
| A1c (%)       |                   |                     |                     |                 |                 |
| Low < 7       | 5.7 (0.6)         | 85 (79.0)            | 45 (42.0)           | 5.9 (0.5)       | 100 (79.0)       | 100 (79.0)          | 1.000 |
| Medium 7-8.9  | 7.8 (0.6)         | 16 (15.0)            | 16 (15.0)           | 7.9 (0.6)       | 17 (13.5)        | 17 (13.5)           | .851 |
| High ≥9       | 9.4 (0.4)         | 6 (5.6)              | 6 (5.6)             | 10.8 (1.4)      | 9 (7.14)         | 9 (7.14)            | .791 |
| SBP (mm Hg)   |                   |                     |                     |                 |                 |
| Low < 120     | 111.4 (6.5)       | 35 (32.7)            | 28 (26.2)           | 110.9 (5.4)     | 27 (21.4)        | 27 (21.4)           | .555 |
| Medium 120-139| 128.5 (5.4)       | 53 (49.5)            | 43 (40.2)           | 128.8 (5.6)     | 58 (46.0)        | 58 (46.0)           | .602 |
| High ≥140     | 148.5 (6.7)       | 19 (17.8)            | 15 (14.0)           | 150.5 (8.2)     | 41 (32.5)        | 41 (32.5)           | .011 |
| DBP (mm Hg)   |                   |                     |                     |                 |                 |
| Low < 80      | 70.7 (6.1)        | 61 (57.0)            | 47 (44.0)           | 72.0 (4.4)      | 42 (33.3)        | 42 (33.3)           | .000 |
| Medium 80-89  | 83.5 (3.1)        | 34 (31.8)            | 32 (30.0)           | 83.9 (2.7)      | 51 (40.5)        | 51 (40.5)           | .176 |
| High ≥90      | 92.5 (2.1)        | 12 (11.2)            | 7 (6.5)             | 95.7 (5.6)      | 33 (26.2)        | 33 (26.2)           | .005 |
| LDL (mg/dL)   |                   |                     |                     |                 |                 |
| Low < 100     | 72.3 (21.30)      | 69 (64.5)            | 63 (59.0)           | 80.0 (12.9)     | 60 (47.6)        | 60 (47.6)           | .012 |
| Medium 100-129| 112.5 (7.8)       | 25 (23.4)            | 21 (19.6)           | 114.1 (8.6)     | 44 (35.7)        | 44 (35.7)           | .045 |
| High ≥130     | 158.0 (21.3)      | 13 (12.2)            | 12 (11.2)           | 145.5 (21.1)    | 22 (17.5)        | 22 (17.5)           | .276 |

Abbreviations: A1c, hemoglobin A1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein cholesterol; SD, standard deviation.

*Proportion of participants taking the respective medication (diabetes, hypertension, and lipids).

**Fisher or χ² test comparing proportion of African Americans and Caucasian in each category.**
Table 3. Predicted Probability of Achieving Each Diabetes Care Goal by Race.

|                          | Adjusted Prevalence Estimates* (95% CI) | P Value for Race Difference |
|--------------------------|----------------------------------------|----------------------------|
|                          | Caucasian | African American |                  |
| A1c controlb              | 0.96 (0.81-0.99) | 0.96 (0.81-0.99) | .955          |
| BP controlc               | 0.77 (0.54-0.90) | 0.61 (0.36-0.82) | .016          |
| LDL Cholesterol controld | 0.46 (0.25-0.68) | 0.33 (0.16-0.55) | .052          |
| ABC control*             | 0.25 (0.10-0.49) | 0.13 (0.05-0.31) | .009          |

Abbreviations: ABC, A1c, BP, and cholesterol; BP, blood pressure; CI, confidence interval; LDL, low density lipoprotein.

*Adjusted prevalence estimates were obtained for each treatment goal by race. Analyses are adjusted for sex, region, study year, age at HIV diagnosis, rank, and diabetes duration.

**Glycemic control was also adjusted for use of diabetes medications.

**Blood pressure control was also adjusted for use of antihypertensive medications.

**Cholesterol control was also adjusted for cholesterol medications.

**Combined control of hemoglobin A1c level, BP, and LDL cholesterol adjusted for all medications.

socioeconomic disparities is unclear. On the one hand, BP levels have consistently been higher for African Americans and this disparity has been recognized for decades. These differences have been attributed to genetic factors and to biological factors, such as increased salt intake sensitivity. On the other hand, this race-biology link has been challenged and some argue these so-called biological differences are products of racial inequality becoming embodied in the biological well-being of racialized groups. Racism or discrimination could also be playing a role in diabetes control disparities, mainly through affecting the quantity and/or quality of healthcare services African Americans receive.

Life-course exposure to socioeconomic challenges may also explain the disparity in BP control. The length of time a person spends growing up in resource-deprived environments (defined by poverty, lack of quality education, or lack of health care) has a significant impact on diabetes risk, diagnosis, and outcomes. In African Americans, the cumulative burden of adverse psychosocial and economic circumstances is associated with adverse health risks. Thus, the adverse health effects life-course socioeconomic challenges may have in African Americans in this study may not be offset by improved access to health care. Addressing the socioeconomic factors that affect diabetes care and outcomes is imperative to achieve equity in prevention and treatment.

Disparities in hypertension prevalence and control may contribute to higher rates of stroke, chronic kidney disease, and congestive heart failure observed among African Americans, in particular those living with HIV. Thus, aggressive management of cardiometabolic diseases should be integrated in HIV care and patient-centered approaches should be employed to address racial disparities in diabetes control. Indeed, the joint clinical guidelines from the US Department of Veterans Affairs and the US Department of Defense and the American Diabetes Association Standards of Medical Care in Diabetes stress the importance of taking into account social determinants when establishing treatment goals and plans. Such patient-centered strategies should be used in HIV care to mitigate the detrimental effects of racial disparities in diabetes control.

This study has limitations. The cross-sectional analysis only provides evidence of associations and may not be reflective of long-term effects. Due to protection of personal health information, we could not use participant age and used age at HIV diagnosis as a surrogate. Military rank is used as a proxy for SES in the US military, which may not capture all aspects of SES relevant to diabetes control (eg, education, income). There were few women in this analysis, which limits study conclusions to mostly men. The differing characteristics between included and excluded participants calls for approaches to overcome missing data issues in analyses. We used the American Diabetes Association 2019 treatment targets and are aware that these differ from targets proposed by other organizations (eg, American College of Cardiology/American Heart Association Blood Pressure guidelines) and that individualized treatment goals are preferred to rigid cutoffs. Finally, our analyses may be limited by the small number of participants in some categories (eg, ABC control); this may also have limited statistical power to find associations.

Conclusion

While HIV and glycemic control are optimal among PWH in this cohort, overall diabetes control is poor. This was more pronounced among African Americans that despite having equal access to health care and equivalent HIV control, have lower rates of BP control and thus ABC control than Caucasians. Factors associated with disparities in BP control should be identified and addressed to improve diabetes management in HIV care. In order to maintain the gains in life expectancy achieved through successful HIV management, comorbidities such as diabetes should be effectively managed with equal progress for all.

Authors’ Note

K.I.G and J.C. designed the study, provided guidance for statistical analyses, provided interpretation of study findings, and drafted the manuscript. R.V. conducted the statistical analyses, contributed to interpretation of findings, critically revised the manuscript, and approved submission. X.C. and S.H.W provided guidance for statistical analyses, contributed to interpretation of findings, critically revised the manuscript, and approved submission. A.G. contributed to interpretation of findings, provided guidance for study conduction, critically revised the manuscript, and approved submission. B.K.A., VCM, and M.K.A. contributed to study design, interpretation of findings, critically revised the manuscript, and approved submission. The views expressed are those of the authors and do not reflect the official views of the Uniformed Services University of the Health Sciences, the National Institutes of Health or the Department of Health and Human Services, the Department of Defense, or the Departments of the Army, Navy or Air Force, or the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The National Institute of Diabetes and Digestive and Kidney Diseases [P30DK111024]; the National Heart, Lung, and Blood Institute [1K01HL149479-01]; the Infectious Disease Clinical Research Program, a Department of Defense program executed through the Uniformed Services University of the Health Sciences; the National Institute of Allergy and Infectious Diseases [Y1-AI-5072]; the Emory University Center for AIDS Research [P30AI050409]; and the Veterans Aging Cohort Study [U01AA020790].

ORCID iD
Jonathan Colasanti, MD, MSPH © https://orcid.org/0000-0002-5491-3388

Supplemental Material
Supplemental material for this article is available online.

References
1. Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010. BMJ Open Diabetes Res Care. 2017;5(1):e000304.
2. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter aids cohort study. Arch Intern Med. 2005;165(10):1179–1184.
3. Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61(3):334–340.
4. Willig AL, Westfall AO, Overton ET, et al. Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. AIDS Res Hum Retroviruses. 2015;31(9):898–904.
5. Buchacz K, Baker RK, Palella FJ Jr, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75.
6. Burkholder GA, Tamhane AR, Safford MM, et al. Racial disparities in the prevalence and control of hypertension among a cohort of HIV-infected patients in the southeastern United States. PLoS One. 2018;13(3):e0194940.
7. Williams DR, Mohammed SA, Leavell J, Collins C. Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. Ann N Y Acad Sci. 2010;1186(1):69–101.
8. Blackwell DL, Martinez ME, Gentleman JF, Sanmartin C, Berthelot JM. Socioeconomic status and utilization of health care services in the United States: findings from a Bional Health Survey. Med Care. 2009;47(11):1136–1146.
9. Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011;93(1):1–9.
10. Chen J, Vargas-Bustamante A, Mortensen K, Ortega AN. Racial and ethnic disparities in health care access and utilization under the affordable care act. Med Care. 2016;54(2):140–146.
11. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
12. Ali MK, Bullard KM, Gregg EW, Del Rio C. A cascade of care for diabetes in the United States: visualizing the gaps. Ann of Intern Med. 2014;161(10):681–689.
13. Colasanti J, Galaviz KI, Christina Mehta C, et al. Room for improvement: the HIV-diabetes care continuum over 15 years in the women’s interagency HIV study. Open Forum Infect Dis. 2018;5(6):ofy121.
14. Miles D. Brief commentary: social determinants of health and treatment targets for type 2 diabetes. Ann Intern Med. 2018;169(4):252.
15. Marconi VC, Grandits GA, Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther. 2010;7(1):14.
16. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009;52(5):574–580.
17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2019;42(suppl 1): S1–S193.
18. Hatzfeld JJ, LaVeist TA, Gaston-Johansson FG. Racial/ethnic disparities in the prevalence of selected chronic diseases among US Air Force members, 2008. Prev Chronic Dis. 2012;9(6):E112.
19. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci. 2014;348(2):135–138.
20. Adyemo A, Gerry N, Chen G, et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLOS Genetics. 2009;5(7):e1000564.
21. Wright JT Jr, Rahman M, Scarpa A, et al. Determinants of salt sensitivity in black and white normotensive and hypertensive women. Hypertension. 2003;42(6):1087–1092.
22. Gravlee CC. How race becomes biology: embodiment of social inequality. Am J Phys Anthropol. 2009;139(1):47–57.
23. Hardeman RR, Medina EM, Kozhimannil KB. Structural racism and supporting black lives—the role of health professionals. N Engl J Med. 2016;375(22):2113–2115.
24. Haire-Joshu D, Hill-Briggs F. The next generation of diabetes translation: a path to health equity. Annu Rev Public Health. 2019;40:391–410.
25. Love C, David RJ, Rankin KM, Collins JW Jr. Exploring weathering: effects of lifelong economic environment and maternal age on low birth weight, small for gestational age, and preterm birth in African-American and white women. Am J Epidemiol. 2010; 172(2):127–134.
26. Conlin PR, Colburn J, Aron D, Pries RM, Tschanz MP, Pogach L. Synopsis of the 2017 U.S. department of veterans affairs/U.S. department of defense clinical practice guideline: management of type 2 diabetes mellitus. *Ann Intern Med.* 2017;167(9):655–663.

27. Colasanti J, Kelly J, Pennisi E, et al. Continuous retention and viral suppression provide further insights into the HIV care continuum compared to the cross-sectional HIV care cascade. *Clin Infect Dis.* 2016;62(5):648–654.

28. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension.* 2018;71(6):1269–1324.

29. Burke BV, Hedin S. Brief commentary: laboratory accuracy of hemoglobin A1c ranges and treatment targets for patients with type 2 diabetes. *Ann Intern Med.* 2018;169(4):253.

30. Hirsch IB, Skyler JS. Brief commentary: confusing treatment guidelines for patients with type 2 diabetes. *Ann Intern Med.* 2018;169(4):253.